| アブストラクト | BACKGROUND: By 8 September 2022, 10 biological monoclonal antibody (mAb) biosimilar products for cancer treatment had been approved and marketed in the United States (US). This study examined adverse event (AE) reporting patterns and disproportionate reporting signals for mAb biosimilars in the US compared to their originator biologics. RESEARCH DESIGN AND METHODS: The US Food and Drug Adverse Event Reporting System database was used to identify AE reports for biological rituximab, bevacizumab, trastuzumab, and their marketed biosimilars. Proportions of patient age, sex and type of reporters of AEs were described for these reports. Reporting odds ratios (RORs) with 95% confidence intervals were calculated to compare reporting disproportionality in serious, death, and specific AEs between mAb biologics/biosimilars (index) and all other drugs. Breslow-Day statistic was used to determine homogeneity in RORs between each mAb biologic-biosimilar pair at p < 0.05. RESULTS: We observed no risk signals of serious or death AE reporting for all three mAb biosimilars. A signal of disproportionate reporting of death was detected between biological and biosimilar bevacizumab (p < 0.05). CONCLUSIONS: Our findings support the similarity in signals of disproportionate AE reporting between mAb originator biologics and biosimilars, except for death between biological and biosimilar bevacizumab. |
|---|
| ジャーナル名 | Expert opinion on biological therapy |
|---|
| Pubmed追加日 | 2023/3/10 |
|---|
| 投稿者 | Xue, Xiangzhong; Truong, Bang; Qian, Jingjing |
|---|
| 組織名 | Department of Health Outcomes Research and Policy, Auburn University Harrison;College of Pharmacy, Auburn, AL, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36892184/ |
|---|
